T-bet RelA Interaction Modulation for IL-2 Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The mechanism by which T-bet controls IL-2 production in Th1 cells is not fully understood, limiting the ability to modulate IL-2 levels effectively.
Innovation Solution
T-bet acts as a repressor of IL-2 gene transcription by interacting with the RelA NF-κB transcription factor, specifically through T-betS508 phosphorylation, regulating the binding of RelA to the IL-2 promoter DNA and thus its transactivation of IL-2 gene expression. Methods are developed to identify compounds that modulate this interaction to either increase or decrease IL-2 production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If T-bet interacts with RelA to repress IL-2 transcription, then IL-2 production is controlled, but the mechanism is not fully understood limiting modulation ability
Solution Approach 1:
The patent identifies T-bet as an intermediary protein that mediates the repression of IL-2 transcription by interacting with RelA. By characterizing this intermediary relationship and its phosphorylation at S508, the patent resolves the mechanism black box, enabling rational drug design to modulate IL-2 production through targeted interference with the T-bet-RelA interaction.
2Adaptability or versatility
If compounds are designed to modulate T-bet-RelA interaction, then IL-2 levels can be controlled, but compound screening and identification becomes complex
Solution Approach 1:
The patent uses the T-bet-RelA interaction as a targetable intermediary step in the IL-2 transcription pathway. By focusing screening efforts on compounds that disrupt or enhance this specific protein-protein interaction, the patent simplifies the screening process while maintaining the ability to effectively modulate IL-2 levels, avoiding the need to screen against the entire transcriptional machinery.
Solution Approach 2:
The patent focuses modulation efforts on a specific local interaction (T-bet-RelA binding at the IL-2 promoter) rather than attempting to control the entire IL-2 transcriptional pathway. This localized approach allows for more targeted and efficient compound screening, reducing complexity while maintaining versatility in IL-2 level control.
Data Source
AI summary
The instant invention is based, at least in part, on the dentification of a mechanism by which T-bet modulates IL2 production. The present invention pertains to methods of identifying agents that modulate the kinase-mediated interaction of T-bet with RelA, as well as methods of use therefore.